KATIE CAMP: Open Payments
NPI 1518566181 · CLINTON, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$642 in 36 payments from 11 companies in 2025. Trend: 2023 $427 · 2024 $184 · 2025 $642
Food & beverage: $642
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 15 | $236 |
| ABBVIE INC. | 5 | $99 |
| Axsome Therapeutics, Inc. | 4 | $88 |
| Otsuka America Pharmaceutical, Inc. | 3 | $60 |
| Novo Nordisk Inc | 2 | $33 |
| E.R. Squibb & Sons, L.L.C. | 2 | $30 |
| Tris Pharma Inc | 1 | $25 |
| Alkermes, Inc. | 1 | $21 |
| Lilly USA, LLC | 1 | $20 |
| Indivior Inc. | 1 | $17 |
Products named: CAPLYTA, VRAYLAR, Auvelity, REXULTI, COBENFY, Dyanavel XR, VIVITROL, MOUNJARO.
Industry payments across LA — which companies pay providers there.
